GAGA Share Market News

[hfe_template id='11223'] [ad_1] Synopsis When Donald Trump is back in the saddle, one thing is certain: Tariff wars. Yes, China will be the biggest target. But for all those who think India will be unaffected, just do a Google search for “Trump on high import duty on Harley Davidson bikes”. A further indication came just a few days ago when he mentioned Brazil and India in the same breath, saying that the two countries were imposing high tariffs and should expect consequences. While it may not become a major issue, there may well be some retaliation. Or the threat of retaliation could be used as a tool to get India to change its stance on some global issue. Or as a quid pro quo: For instance, a push for lower duties on EVs, especially cars – a move that could help Trump’s biggest backer Elon Musk and his Tesla. But one sector which would be relatively safe could be pharma, and there are reasons for it. And mind you, we are using the word “relatively”. As the world gets ...

[hfe_template id='11223'] [ad_1] Shares of Lupin will remain in focus on Thursday after the drugmaker received approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for HIV tablets emtricitabine and tenofovir alafenamide tablets, 200 mg/25 mg. "We wish to confirm that the Company has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Alafenamide Tablets, 200 mg/25 mg, to market a generic equivalent of Descovy® Tablets, 200 mg/25 mg of Gilead Sciences, Inc," Lupin said in an exchange filing. The approval allows Lupin to market a generic version of Descovy tablets, a product originally developed by Gilead Sciences Inc. Lupin is one of the first companies to receive approval for this generic formulation, making it eligible for 180 days of shared generic exclusivity in the US market. The product will be manu...